Waters Corp

WAT

Market cap $31.3B

After losing some value lately, a hammer chart pattern has been formed for Waters (WAT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

MILFORD, Mass., Feb. 23, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

Headlines: Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1  Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

WAT tops Q4 estimates as revenues rise 7% Y/Y, with strong Pharma and Europe growth, and upbeat 2026 sales and earnings outlook.

Waters (WAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.

Waters Corporation (NYSE: WAT) stock is trading lower on Monday after the company released fourth-quarter 2025 financial results and issued fiscal 2026 guidance.

Waters Corporation (WAT) Q4 2025 Earnings Call Transcript

Waters (WAT) came out with quarterly earnings of $4.53 per share, beating the Zacks Consensus Estimate of $4.5 per share. This compares to earnings of $4.1 per share a year ago.